Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial reached its planned enrollment target, but the primary efficacy endpoint did not achieve the prespecified level of statistical significance [3]. Group 2: Management Statements - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3].

Core Viewpoint - The market anticipates Gossamer Bio (GOSS) will report a year-over-year decline in earnings due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Gossamer Bio is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year change of -26.7% [3]. - Revenues are projected to be $7.6 million, down 19% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.33% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Gossamer Bio is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -30.21% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with predictive power being significant for positive readings only [9][10]. - Gossamer Bio's combination of a negative Earnings ESP and a Zacks Rank of 2 makes it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Gossamer Bio was expected to post a loss of $0.19 per share but actually reported a loss of -$0.21, resulting in a surprise of -10.53% [13]. - Over the past four quarters, Gossamer Bio has beaten consensus EPS estimates three times [14]. Industry Comparison - Adherex Technologies Inc. (FENC), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $0.03 per share, indicating a year-over-year change of +150% [18]. - Revenues for Adherex are expected to be $14.97 million, up 88.8% from the previous year, with a significant revision of the consensus EPS estimate by 403.6% higher over the last 30 days [19].

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Gossamer Bio Inc (NASDAQ:GOSS) is highlighted as an oversold stock with an RSI near or below 30 [2][3] - Brainsway Ltd – ADR (NASDAQ:BWAY) is also listed among the major oversold players in the health care sector [2][3] - Definitive Healthcare Corp (NASDAQ:DH) is included in the list of oversold stocks, indicating potential for recovery [2][3]

Core Insights - Gossamer Bio, Inc. experienced a significant decline of over 60% in its stock value following the Phase 3 PROSERA trial results for seralutinib, which missed its primary endpoint [1] - The company's CEO had previously set expectations for positive results in February 2026, indicating optimism about the trial's outcome [1] - The trial's statistical plan required a significance level of alpha = 0.025, which was not disclosed to investors, leading to a gap between management's guidance and the actual statistical requirements [1] Company Performance - The actual p-value from the PROSERA trial was reported at 0.032, which, while passing the conventional 0.05 threshold, did not meet the more stringent 0.025 requirement [1] - The lack of disclosure regarding the heightened statistical threshold created an elevated risk for investors who relied on the company's forward-looking statements [1] Investor Impact - Shareholders who invested in Gossamer Bio and incurred losses are encouraged to seek legal advice regarding their rights [1] - The investigation focuses on the discrepancy between the company's optimistic guidance and the undisclosed statistical hurdles that contributed to the trial's failure [1]

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial aimed to demonstrate a treatment effect in a patient population that the company believed was well-suited for the study [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were targeted and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

Core Viewpoint - Gossamer Bio, Inc. is currently under investigation for potential fraud, providing an opportunity for investors to join the legal proceedings initiated by the Schall Law Firm [1] Group 1 - The investigation is focused on allegations of fraudulent activities related to Gossamer Bio, Inc. [1] - Investors are encouraged to participate in the investigation to seek potential recovery of losses [1]

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]

Core Viewpoint - Gossamer Bio, Inc. is under investigation for potential securities fraud following the failure of its Phase 3 PROSERA trial for seralutinib, which led to a significant drop in stock price [1][2]. Company Performance - On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial evaluating seralutinib in pulmonary arterial hypertension did not meet its primary endpoint [2]. - Following this announcement, Gossamer's stock price fell by $1.71 per share, representing an 80.14% decline, closing at $0.423 per share on the same day [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Gossamer investors regarding possible securities fraud or unlawful business practices by the company and its officers and/or directors [1].

Core Viewpoint - Gossamer Bio (GOSS) has experienced a significant downtrend, losing 82.5% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for GOSS [2][5]. - A hammer pattern forms when there is a small difference between opening and closing prices, with a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for GOSS serve as a bullish indicator, correlating strongly with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for GOSS has increased by 8.6%, indicating that analysts expect better earnings than previously predicted [8]. - GOSS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Gossamer Bio (GOSS) has experienced a significant decline of 85.1% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - GOSS has an RSI reading of 13.04, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Indicators - Analysts covering GOSS have raised earnings estimates for the current year, resulting in an 8.6% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7]. - GOSS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].